Trial Profile
Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2019
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- Acronyms PACSA; PACSA-ORL02
- Sponsors UNICANCER
- 25 Oct 2019 Status changed from active, no longer recruiting to completed.
- 06 Feb 2019 Planned End Date changed from 1 Aug 2018 to 1 Sep 2019.
- 11 Oct 2016 Results assessing efficacy of pazopanib including tumor growth rates analysis presented at the 41st European Society for Medical Oncology Congress.